Physician
Owensboro Medical Practice, PLLC
Owensboro Medical Practice, PLLC was paid $4.89M by Medicaid between Jan 2018 and Dec 2024, across 125 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 43% of everything it billed.
33Billing provider infoOWENSBORO MEDICAL PRACTICE, PLLC
OWENSBORO, KY 42303
OWENSBORO, KY 42303
33aNPI1851315105assigned 07/27/2006
33bProvider typeFamily Medicine Physician
28Total paid$4.89M
24GClaims252,713
24DCodes billed125
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Family Medicine Physician providers in Kentucky
Rank by total paid#13 of 352
Median peer was paid$90K
This provider vs. median55×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 34,958 | $712K | |
| 2019 | 44,001 | $693K | |
| 2020 | 34,164 | $507K | |
| 2021 | 32,236 | $603K | |
| 2022 | 37,256 | $771K | |
| 2023 | 35,278 | $738K | |
| 2024incomplete | 34,820 | $865K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 43% | 56,551 | 50,258 | $2.10M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 27,047 | 22,226 | $720K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 5.5% | 3,103 | 2,852 | $271K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | 4.2% | 2,782 | 2,562 | $205K |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | 3.7% | 5,291 | 4,821 | $183K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 3.6% | 16,796 | 11,267 | $178K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.1% | 4,395 | 3,969 | $151K |
| 93000 | 1.3% | 6,938 | 6,299 | $62K | |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 1.1% | 4,096 | 3,675 | $54K |
| 93015 | 1.1% | 1,229 | 1,106 | $52K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | 1.1% | 2,005 | 1,811 | $51K |
| 78452 | Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress | 1.0% | 337 | 309 | $50K |
113 more codes
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 2,868 | $47K |
| 78492 | <1% | 207 | $46K | |
| 99204 | Doctor's office visit, new patient (more involved) | <1% | 571 | $42K |
| 80061 | Lipid panel | <1% | 4,654 | $35K |
| 80050 | General health panel | <1% | 803 | $34K |
| 82607 | <1% | 3,734 | $33K | |
| 93880 | <1% | 546 | $32K | |
| 99232 | Hospital visit by a doctor, follow-up day | <1% | 2,390 | $30K |
| 93224 | <1% | 477 | $28K | |
| 93970 | <1% | 304 | $28K | |
| 99308 | Subsequent nursing facility care, per day, straightforward | <1% | 5,841 | $25K |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 6,685 | $21K |
| 93297 | <1% | 2,769 | $20K | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,757 | $20K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 1,537 | $20K |
| 78431 | <1% | 63 | $19K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 5,039 | $18K |
| G2066 | Interrogation device evaluation(s), (remote) up to 30 days; implantable cardiovascular physiologic monitor system, implantable loop recorder system, or subcutaneous cardiac rhythm monitor system, remote data acquisition(s), receipt of transmissions and technician review, technical support and distribution of results | <1% | 2,574 | $18K |
| 93458 | <1% | 48 | $18K | |
| A9555 | Rubidium rb-82, diagnostic, per study dose, up to 60 millicuries | <1% | 253 | $14K |
| 36415 | Collection of venous blood by venipuncture | <1% | 19,605 | $13K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,604 | $13K |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 2,728 | $13K |
| 93296 | <1% | 1,277 | $12K | |
| 80305 | <1% | 1,404 | $12K | |
| 93295 | <1% | 477 | $12K | |
| 93793 | <1% | 2,906 | $11K | |
| 93971 | <1% | 279 | $11K | |
| 80053 | Comprehensive metabolic panel | <1% | 2,988 | $11K |
| 83735 | <1% | 2,460 | $10K | |
| 99223 | Prolong inpt eval add15 m | <1% | 315 | $10K |
| 85610 | <1% | 4,397 | $9K | |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 8,527 | $9K |
| 80076 | <1% | 2,114 | $8K | |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 468 | $8K |
| J1245 | Injection, dipyridamole, per 10 mg | <1% | 1,081 | $6K |
| 75574 | <1% | 28 | $6K | |
| 93299 | <1% | 740 | $6K | |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 482 | $6K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 2,977 | $5K |
| 93294 | <1% | 574 | $5K | |
| A9502 | Technetium tc-99m tetrofosmin, diagnostic, per study dose | <1% | 176 | $5K |
| 84439 | <1% | 849 | $5K | |
| P9603 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled | <1% | 1,895 | $4K |
| 83880 | <1% | 282 | $4K | |
| 99203 | Doctor's office visit, new patient (routine) | <1% | 74 | $4K |
| 84550 | <1% | 1,223 | $4K | |
| J0280 | Injection, aminophyllin, up to 250 mg | <1% | 975 | $3K |
| 99152 | <1% | 263 | $3K | |
| 99211 | Office or other outpatient visit for the evaluation and management of an established patient, minimal severity | <1% | 449 | $3K |
| 93922 | <1% | 178 | $3K | |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 47 | $3K |
| 93925 | <1% | 44 | $3K | |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 96 | $2K |
| 95800 | <1% | 15 | $2K | |
| 75635 | <1% | 14 | $2K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 28 | $2K |
| 81001 | <1% | 1,487 | $2K | |
| 93298 | <1% | 155 | $1K | |
| 83090 | <1% | 267 | $1K | |
| 99318 | <1% | 257 | $1K | |
| 99441 | <1% | 119 | $1K | |
| 87210 | <1% | 237 | $1K | |
| 90688 | <1% | 130 | $946.56 | |
| 82043 | <1% | 263 | $928.60 | |
| 99426 | <1% | 162 | $905.36 | |
| 87220 | <1% | 225 | $741.94 | |
| 99335 | <1% | 36 | $554.55 | |
| G0439 | Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | <1% | 546 | $477.90 |
| G2012 | Brief communication technology-based service, e.g. virtual check-in, by a physician or other qualified health care professional who can report evaluation and management services, provided to an established patient, not originating from a related e/m service provided within the previous 7 days nor leading to an e/m service or procedure within the next 24 hours or soonest available appointment; 5-10 minutes of medical discussion | <1% | 109 | $428.31 |
| 87807 | <1% | 43 | $424.91 | |
| 99309 | Subsequent nursing facility care, per day, low to moderate complexity | <1% | 154 | $416.57 |
| 99336 | <1% | 23 | $393.02 | |
| 84480 | <1% | 34 | $375.00 | |
| 99153 | Mod sedat endo service >5yrs | <1% | 50 | $357.42 |
| J2785 | Injection, regadenoson, 0.1 mg | <1% | 43 | $289.06 |
| 82248 | <1% | 88 | $285.74 | |
| 99497 | <1% | 38 | $279.44 | |
| J1020 | Injection, methylprednisolone acetate, 20 mg | <1% | 19 | $226.06 |
| 99306 | Prolong nursin fac eval 15m | <1% | 59 | $200.05 |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 13 | $188.75 |
| 84403 | <1% | 12 | $180.70 | |
| G0471 | Collection of venous blood by venipuncture or urine sample by catheterization from an individual in a skilled nursing facility (snf) or by a laboratory on behalf of a home health agency (hha) | <1% | 646 | $177.00 |
| 80164 | <1% | 43 | $150.80 | |
| 3008F | <1% | 4,054 | $134.20 | |
| J1250 | Injection, dobutamine hydrochloride, per 250 mg | <1% | 14 | $118.65 |
| 81003 | <1% | 146 | $83.61 | |
| G0506 | Comprehensive assessment of and care planning for patients requiring chronic care management services (list separately in addition to primary monthly care management service) | <1% | 32 | $82.76 |
| 90686 | <1% | 13 | $78.42 | |
| 82728 | <1% | 29 | $75.75 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 17 | $57.76 |
| 84466 | <1% | 17 | $56.72 | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 47 | $35.88 |
| 99406 | <1% | 12 | $34.25 | |
| 36416 | <1% | 18 | $32.70 | |
| 83540 | <1% | 19 | $28.76 | |
| J3420 | Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | <1% | 65 | $24.68 |
| G0444 | Annual depression screening, 5 to 15 minutes | <1% | 73 | $13.50 |
| P9604 | Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge | 0% | 212 | $0.00 |
| G8752 | Most recent systolic blood pressure < 140 mmhg | 0% | 650 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 1,040 | $0.00 |
| 3078F | 0% | 218 | $0.00 | |
| 3077F | 0% | 54 | $0.00 | |
| 3044F | 0% | 339 | $0.00 | |
| 3074F | 0% | 486 | $0.00 | |
| 3079F | 0% | 178 | $0.00 | |
| G8754 | Most recent diastolic blood pressure < 90 mmhg | 0% | 735 | $0.00 |
| G0008 | Administration of influenza virus vaccine | 0% | 75 | $0.00 |
| 3075F | 0% | 37 | $0.00 | |
| 3080F | 0% | 74 | $0.00 | |
| 87077 | 0% | 12 | $0.00 | |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 48 | $0.00 |
| 3061F | 0% | 12 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialBEYKE, FRANCES (ADMINISTRATION)